- Northway Biotech is completing a €61 million, 3,500-square-meter cell therapy and personalized medicine center in Vilnius, Lithuania, expected to begin operations in the third quarter of this year.
- The facility will feature 20 cGMP-compliant production lines and support contract manufacturing of cell therapies, including advanced therapy medicinal products (ATMPs), for global clients.
Northway Biotech is finalizing the installation of a new 3,500-square-meter Innovative Cell Therapy and Personalized Medicine Center in Vilnius, Lithuania. The facility, being developed by Stem Cell Research Center, a company within the Northway group, is expected to begin operations in the third quarter of this year. The project represents an investment of €61 million funded through private capital and financing from the national development bank ILTE.
The new center is being built within the Bio City III project at the Vilnius City Innovation Industrial Park and will focus on the contract manufacturing of advanced therapy medicinal products (ATMPs). The facility will include 20 independent cGMP-compliant production lines, integrated quality control laboratories, advanced cleanroom systems, and isolated manufacturing infrastructure designed for sensitive cell therapies. According to the company, the site will enable the simultaneous production of individualized therapies while maintaining sterility, traceability, and cross-contamination controls.
Northway Biotech said the center is intended to address growing demand for manufacturing capacity in the cell and gene therapy sector, including CAR-T therapies. The company aims to provide contract manufacturing services for university hospitals, biotechnology companies, pharmaceutical companies, and research organizations developing advanced therapies.
“In recent years, medicine has been undergoing a fundamental transformation. We are moving toward complete personalization, where the patient’s own modified cells become the medicine. The company’s goal is to create large-scale contract manufacturing infrastructure to help advanced therapies reach patients more quickly and at greater scale.”
Prof. Vladas Algirdas Bumelis
The facility is expected to employ around 100 specialists and will be integrated with Northway’s nearby Gene Therapy Center, which has been developing and manufacturing gene therapy products since 2024. The company said this integration is intended to streamline the manufacturing process from genetic material preparation through final cell therapy production, supporting the development of a broader biotechnology ecosystem focused on cell, gene, and recombinant protein therapies.
